The Clap Novavax’s (NASDAQ: NVAX) COVID-19 vaccine is close to full authorization as the Food & Drug Administration (FDA) approves a key step.
The deets In a meeting to recommend authorizing the shot for use in the U.S, FDA officials voted unanimously in favor of the two-dose vaccine. The vaccine can only be administered to ages 18 years & older.
Now what? What now remains is clearance for distribution, which Novavax could receive as early as tomorrow, Friday, June 10, 2022.
Why this matters Pfizer & Moderna’s vaccines led the way in terms of most U.S. vaccinations, but there remain around 27 million people who haven’t taken them. Novavax believes its drug could appeal to those who seek a vaccine alternative to the current mRNA vaccines.